Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.
Sponsor: Amgen
Protocol: POE14-01
Principal investigator: Jessica Boklan, MD
Site: Phoenix Children's Hospital
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Sponsor: Genentech
Protocol: GO40871
Estimated accrual years: 5 years (in 3 phases)
Read more about this trial at ClinicalTrials.gov
Sponsor: Puma
Protocol: POE16-01
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Estimated accrual years: 1.0 (Phase I); 1.5 (Phase II)
Read more about this trial at ClinicalTrials.gov
Sponsor: Dr. Kamens
Protocol: POE22-01
Principal investigator: Jennifer Kamens, MD
Site: Stanford University
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Programs
Return to Top
Receive updates on POETIC new projects and activities.